Kaplan Fox & Kilsheimer LLP Reminds Eagle Pharmaceuticals Investors of a Class Action and Upcoming Deadline
30 déc. 2023 11h00 HE
|
Kaplan Fox & Kilsheimer LLP
Kaplan Fox & Kilsheimer LLP Reminds Eagle Pharmaceuticals Investors of a Class Action and Upcoming Deadline
Eagle Pharmaceuticals Investor Update: Kaplan Fox & Kilsheimer LLP Notifies Eagle Pharmaceuticals Investors of a Class Action and Upcoming Deadline
13 déc. 2023 12h30 HE
|
Kaplan Fox & Kilsheimer LLP
Kaplan Fox notifies investors of Class Action filed against Eagle Pharmaceuticals.
EGRX Investor Alert: Kaplan Fox & Kilsheimer LLP Investigates Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX)
07 déc. 2023 08h00 HE
|
Kaplan Fox & Kilsheimer LLP
Kaplan Fox & Kilsheimer LLP is investigating potential claims on behalf of investors who purchased securities of Eagle Pharmaceuticals, Inc.
Kaplan Fox & Kilsheimer LLP Investigates Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX)
04 déc. 2023 08h00 HE
|
Kaplan Fox & Kilsheimer LLP
Kaplan Fox is investigating potential claims on behalf of investors who purchased securities of Woodcliff Lake, New Jersey-based Eagle Pharmaceuticals, Inc
Kaplan Fox & Kilsheimer LLP Investigates Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX)
30 nov. 2023 16h30 HE
|
Kaplan Fox & Kilsheimer LLP
Kaplan Fox is investigating potential claims on behalf of investors who purchased securities of Woodcliff Lake, New Jersey-based Eagle Pharmaceuticals.
Kaplan Fox & Kilsheimer LLP Investigates Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX)
29 nov. 2023 14h50 HE
|
Kaplan Fox & Kilsheimer LLP
Kaplan Fox is investigating potential claims on behalf of investors who purchased securities of Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX).